Lv2
120 积分 2021-07-12 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
9天前
已完结
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research
19天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2个月前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
2个月前
已完结
Claudin 18.2 as a novel therapeutic target
3个月前
已完结
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2
3个月前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
7个月前
已关闭
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
9个月前
已完结
皖公网安备34019202002308
